Download PDF
Pharmacopsychiatry 2008; 41: S28-S31
DOI: 10.1055/s-2008-1080913
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Neurological Disease: Are Systems Approaches the Way Forward?

N. Le Novère 1
  • 1EMBL-EBI, Hinxton, Cambridge, UK
Further Information

Publication History

Publication Date:
28 August 2008 (online)

Also available at
    Permissions and Reprints

Abstract

Most neurological diseases are multifactorial diseases, where environmental conditions combine with genetic background or somatic mutations to trigger a pathological state. In the case of Parkinson's Disease and Schizophrenia, recent research revealed that susceptibility genes coded for proteins involved at different steps of specific metabolic networks and cellular processes. Comprehension of the pathology of those diseases is therefore very likely to benefit from Systems approaches. This is also true of their symptomatology, affecting neurological systems at molecular, cellular, and microcircuit levels.

References

  • 1 Braver TS, Barch DM, Cohen JD. Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function.  Biol Psychiatry. 1999;  46 312-328
    CrossrefPubMedGoogle Scholar
  • 2 Brown JW, Bullock D, Grossberg S. How laminar frontal cortex and basal ganglia circuits interact to control planned and reactive saccades.  Neural Netw. 2004;  17 471-510
    CrossrefPubMedGoogle Scholar
  • 3 Butcher J. Neuroproteomics comes of age.  Lancet. 2007;  6 850-851
    PubMedGoogle Scholar
  • 4 Calabresi P, Picconi B, Parnetti L, DiFilippo M. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance.  Lancet Neurol. 2006;  5 ((11)) 974-983
    CrossrefPubMedGoogle Scholar
  • 5 Calzone L, Gelay A, Zinovyev A, Radvanyi F, Barillot E. A comprehensive modular map of molecular interactions in RB/E2F pathway.  Mol Sys Biol. 2008;  , in the press
    PubMedGoogle Scholar
  • 6 Camargo LM, Collura V, Rain JC, Mizuguchi K, Hermjakob H, Kerrien S, Bonnert TP, Whiting PJ, Brandon NJ. Disrupted in schizophrenia 1 interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia.  Mol Psych. 2007;  12 74-86
    Google Scholar
  • 7 Carpenter WT, Buchanan RW. Schizophrenia.  N Engl J Med. 1994;  330 681-690
    CrossrefPubMedGoogle Scholar
  • 8 Contreras-Vidal JL, Stelmach GE. A neural model of basal ganglia-thalamocortical relations in normal and parkinsonian movement.  Biol Cybern. 1995;  73 467-476
    CrossrefPubMedGoogle Scholar
  • 9 Cookson MR. The biochemistry of Parkinson's disease.  Annu Rev Biochem. 2005;  74 29-52
    CrossrefPubMedGoogle Scholar
  • 10 Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis.  Cell Mol Neurobiol. 2006;  26 365-384
    PubMedGoogle Scholar
  • 11 Cutsuridis V, Perantonis S. A neural network model of Parkinson's disease bradykinesia.  Neural Netw. 2006;  19 354-374
    CrossrefPubMedGoogle Scholar
  • 12 Exner N, Treske B, Paquet D, Holmström K, Schiesling C, Gispert S, Carballo-Carbajal I, Berg D, Hoepken HH, Gasser T, Krüger R, Winklhofer KF, Vogel F, Reichert AS, Auburger G, Kahle PJ, Schmid B, Haass C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin.  J Neurosci. 2007;  27 12413-12418
    CrossrefPubMedGoogle Scholar
  • 13 Fernandez E, Schiappa R, Girault JA, Le Novère N. DARPP-32 is a robust integrator of dopamine and glutamate signals.  PLoS Comput Biol. 2006;  2 e176
    CrossrefPubMedGoogle Scholar
  • 14 Garcia L, D’Alessandro G, Fernagut PO, Bioulac B, Hammond C. Impact of high-frequency stimulation parameters on the pattern of discharge of subthalamic neurons.  J Neurophysiol. 2005;  94 3662-3669
    CrossrefPubMedGoogle Scholar
  • 15 Gupta S, Bisht SS, Kukreti R, Jain S, Brahmachari SK. Boolean network analysis of a neurotransmitter signaling pathway.  J Theor Biol. 2007;  244 463-469
    CrossrefPubMedGoogle Scholar
  • 16 Han SD, Nestor PG, Shenton ME, Niznikiewicz M, Hannah G, MacCarley RW. Associative memory in chronic schizophrenia: a computational model.  Schizophr Res. 2003;  61 255-263
    CrossrefPubMedGoogle Scholar
  • 17 Humphries MD, Stewart RD, Gurney KN. A physiologically plausible model of action selection and oscillatory activity in the basal ganglia.  J Neurosci. 2006;  26 12921-12942
    CrossrefPubMedGoogle Scholar
  • 18 Kaushik P, Gorin F, Vali S. Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis.  J Comput Neurosci. 2007;  22 147-160
    CrossrefPubMedGoogle Scholar
  • 19 Justice JB, Nicolaysen LC, Michael AC. Modeling the dopaminergic nerve terminal.  J Neurosci Methods. 1988;  22 239-252
    CrossrefPubMedGoogle Scholar
  • 20 Le Novère . The long journey to a Systems Biology of neuronal function.  BMC Systems Biology. 2007;  1 28
    CrossrefPubMedGoogle Scholar
  • 21 Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.  N Engl J Med. 1998;  339 1105-1111
    CrossrefPubMedGoogle Scholar
  • 22 Lindskog M, Kim M, Wikström MA, Blackwell KT, Kotaleski JH. Transient calcium and dopamine increase PKA activity and DARPP-32 phosphorylation.  PLoS Comput Biol. 2006;  2 e119
    CrossrefPubMedGoogle Scholar
  • 23 Mackie S, Millar JK, Porteous DJ. Role of DISC1 in neural development and schizophrenia.  Curr Opin Neurobiol. 2007;  17 95-102
    CrossrefPubMedGoogle Scholar
  • 24 Markram H. The blue brain project.  Nat Rev Neurosci. 2006;  7 153-160
    CrossrefPubMedGoogle Scholar
  • 25 Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease.  Annu Rev Neurosci. 2005;  28 57-87
    CrossrefPubMedGoogle Scholar
  • 26 Nicholson C. Interaction between diffusion and Michaelis-Menten uptake of dopamine after iontophoresis in striatum.  Biophys J. 1995;  68 1699-1715
    CrossrefPubMedGoogle Scholar
  • 27 Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.  Nat Medecine. 2007;  13 1102-1107
    Google Scholar
  • 28 Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, Macdonald N, Wood NW, Martins ML, Downward J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.  Nat Cell Biol. 2007;  9 1243-1252
    CrossrefPubMedGoogle Scholar
  • 29 Rao SS, Hofmann LA, Shakil A. Parkinson's disease: diagnosis and treatment.  Amer Family Phys. 2006;  74 2046-2054
    PubMedGoogle Scholar
  • 30 Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia.  Neuron. 2006;  52 139-153
    CrossrefPubMedGoogle Scholar
  • 31 Ruppin E, Reggia JA, Horn D. Pathogenesis of schizophrenic delusions and hallucinations: a neural model.  Schizophr Bull. 1996;  22 105-123
    PubMedGoogle Scholar
  • 32 Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine.  J Clin Invest. 2006;  116 1744-1754
    CrossrefPubMedGoogle Scholar
  • 33 Schapira AHV, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease.  Nat Rev Drug Disc. 2006;  5 845-854
    CrossrefPubMedGoogle Scholar
  • 34 Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases.  Neurochem Int. 2007;  51 105-111
    CrossrefPubMedGoogle Scholar
  • 35 Thanvi BR, Lo TCN. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.  Postgrad Med J. 2004;  80 452-458
    CrossrefPubMedGoogle Scholar
  • 36 Traub R, Wong RSK. Cellular mechanism of neuronal synchronisation in epilepsy.  Science. 1982;  216 745-747
    CrossrefPubMedGoogle Scholar
  • 37 Traub R, Contreras D, Cunningham M, Murray H, LeBeau F, Roopun A, Bibbig A, Wilent W, Higley M, Whittington M. Single-column thalamocortical network model exhibiting gamma oscillations, sleep spindles, and epileptogenic bursts.  J Neurophysiol. 2005;  93 2194-2232
    PubMedGoogle Scholar
  • 38 Weihofen A, Ostaszewski B, Minami Y, Selkoe DJ. Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1.  Hum Mol Genet. 2008;  17 602-616
    PubMedGoogle Scholar
  • 39 Wolf JA, Moyer JT, Lazarewicz MT, Contreras D, Benoit-Marand M, O’Donnell P, Finkel LH. NMDA/AMPA ratio impacts state transitions and entrainment to oscillations in a computational model of the nucleus accumbens medium spiny projection neuron.  J Neurosci. 2005;  25 9080-9095
    CrossrefPubMedGoogle Scholar

Correspondence

N. Le Novère

Computational Neurobiology

EMBL-EBI

Wellcome-Trust Genome Campus

Hinxton

Cambridge

CB10 1SD

UK

Phone: +44/0/1223 494 521

Fax: +44/0/1223 494 468

Email: lenov@ebi.ac.uk

      >